Buy Portrazza (necitumumab)

What is Portrazza (necitumumab) for?

Buy Portrazza (necitumumab). Portrazza (necitumumab) is a treatment for people with a type of lung cancer. It works with two other medicines, gemcitabine and cisplatin.

How does Portrazza (necitumumab) work?

Necitumumab is a special protein that targets EGFR on cancer cells. EGFR helps cells grow and divide.

In cancer, EGFR works too much. Necitumumab blocks EGFR. This slows down cancer growth and spread.

Where has Portrazza (necitumumab) been approved?

Portrazza (necitumumab) is approved for advanced lung cancer in several places:

• Food and Drug Administration (FDA), USA, November 11, 2015
• European Medical Agency (EMA), European Union, March 4, 2016
• Health Canada, March 16, 2017

This medicine might be approved in other places too. If you have questions, contact our support team.

How is Portrazza (necitumumab) taken?

Portrazza is given intravenously (through a vein) in a clinical setting, usually every week in combination with chemotherapy. The infusion process typically takes about one hour, during which you will be monitored closely for any adverse reactions. Your healthcare provider will determine the optimal dosage and treatment schedule based on your individual needs and response to therapy.
In conclusion, Portrazza (necitumumab) represents a significant advancement in the treatment of lung cancer, offering new hope to patients facing this challenging diagnosis. By targeting EGFR and enhancing the immune response against cancer cells, Portrazza helps to slow down disease progression and improve outcomes. If you or a loved one have been diagnosed with advanced NSCLC, talk to your healthcare provider about whether Portrazza may be a suitable treatment option for you. Remember, early intervention and personalized care are key to fighting cancer successfully.

The usual dose is:

• 800 mg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle

It’s given with gemcitabine and cisplatin for up to 6 cycles. Then, it’s used alone if the disease hasn’t gotten worse.

Warning: Closely monitor serum electrolytes: cardiopulmonary arrest and/or sudden death occurred in 3% of patients treated with Portrazza in combination with gemcitabine and cisplatin.

For more details, see the official prescribing information. Always talk to your doctor about your treatment.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known side effects of Portrazza (necitumumab)?

Common side effects

Common side effects include:

• skin reactions (rash)
• hypomagnesemia
• venous thromboembolic events.

Serious side effects

Serious side effects include:

• skin reactions
• venous thromboembolic events: cardiopulmonary arrest and/or sudden death occurred in 3% of patients
• hypomagnesemia occurred in 83% of patients and was severe in 20%.

Use in a specific population

Portrazza (necitumumab) can be fatal for a fetus. It’s advised to avoid pregnancies and breast feeding.

Buy Perjeta (Pertuzumab)